CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2018 Financial Results
-Obtained Approvals of CTAs in Multiple Countries for CTX001 in β-thalassemia and SCD- -Initiation of Clinical Trials for CTX001 in β-thalassemia and SCD on Track for 2018- -Preclinical Studies for CTX110 Targeting CD19+ Malignancies Have Begun- - …